Drug Trial Radar · NCT07008703
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
Last checked: Nov 20, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Mar 27, 2024
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer pain. The study includes two stages: a single-arm, open-label, dose-escalation and dose-expansion Phase Ib followed by a randomized, double-blind, placebo-controlled Phase IIa.
Conditions
- Cancer Pain
Interventions
Injection of humanized nerve growth factor (NGF) antibodyDrug
Subcutaneous injection, 20mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) Events (NCI-CTCAE V5.0)Time frame: Up to Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.